Recent Updates
Recently added Catalysts

IMC-R117C

Phase 1

Cancer | Small molecule | Oncology |Immunocore Holdings plc|Last Updated: Jan 28, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
ACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment600
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06840119Phase 1/2 Study of IMC-R117C in Selected Advanced CancersPHASE1 RECRUITING 600 — — Jan 10, 2024Nov 30, 2027Jan 28, 202613 Australia, Belgium +4
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Dose Escalation: Percentage of participants with ≥1 dose-limiting toxicity (DLT)
Up to ~24 months
Dose Escalation: Percentage of participants with ≥1 adverse event (AE)
Up to ~24 months
Dose Escalation: Percentage of participants with ≥1 serious adverse event (SAE)
Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in electrocardiogram (ECG) recordings
Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in vital signs
Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in laboratory results
Up to ~24 months
Dose Escalation: Percentage of participants with a dose interruption, reduction, or discontinuation
Up to ~24 months
Expansion: Best Overall Response (BOR) as Determined by RECIST v1.1
Up to ~24 months
Secondary Endpoints
Dose Escalation: Best Overall Response (BOR) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination
Up to ~36 months
Dose Escalation: Duration of Response (DOR) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination
Up to ~36 months
Dose Escalation: Progression-free survival (PFS) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination
Up to ~36 months
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm A: IMC-R117C Monotherapy Dose-EscalationEXPERIMENTALParticipants receive IMC-R117C intravenous (IV) infusion.
Arm B: IMC-R117C Combination Dose-EscalationEXPERIMENTALParticipants receive IMC-R117C IV infusion in combination with standard of care chemotherapy and antiangiogenic agent
Arm C: IMC-R117C Combination Dose-EscalationEXPERIMENTALParticipants receive IMC-R117C IV infusion with targeted therapies
Arm D: Control ArmACTIVE_COMPARATORParticipants receive standard of care chemotherapy and antiangiogenic agent
Interventions
NameTypeDescription
IMC-R117CDRUGIV infusion
Chemotherapy drugDRUGIV infusion
Kinase inhibitorDRUGoral
Antiangiogenic AgentDRUGIV infusion
Monoclonal antibodyDRUGIV infusion
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites13

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * HLA-A\*02:01-positive * Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma * Archived or fresh tumor tissue sample that must be confirmed as adequate * Evaluable...

Countries:AustraliaBelgiumGermanyItalyNetherlandsSpain
Unlock Eligibility Criteria
Competitive Landscape -Cancer 5 trials
CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520 / GEH200521 - Part A
Zimmer Biomet Holdings, Inc.ZBH1 — Undisclosed
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT06840119Phase: PHASE1/PHASE2 → PHASE1
LOWMay 24, 2026NCT06840119studyFirstPostDate: changed